Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that Grant Thornton UK LLP has been appointed as the Group’s auditor, with immediate effect. Lakin Rose Limited has resigned as the auditor of Arecor Limited.
Arecor announces appointment of Grant Thornton as auditor
The Board’s decision to appoint auditors for the Group was made following a consultation process. Grant Thornton was chosen based on their public company expertise, reputation and experience. Lakin Rose has confirmed that it is not aware of any circumstances connected with its cessation as auditor of Arecor Limited that it considers should be brought to the attention of the Board, creditors or shareholders.
In accordance with section 327(c) of the Corporations Act 2001, a resolution will be tabled at the Company’s 2021 Annual General Meeting to ratify the appointment of Grant Thornton as the Group’s auditor.
The Board of Directors would like to take this opportunity to thank Lakin Rose UK LLP for their assistance and services to Arecor Limited.
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
Advancing today's therapies to enable healthier lives.